University of California San Francisco Sep 12 2025 Urothelial carcinoma (UC) is the second most common genitourinary cancer, leading to over 16,000 deaths a year in the United States. Despite recent advances, the 5-year survival rate for metastatic UC remains around five to ten percent. The first FDA-approved antibody-drug conjugate therapy for metastatic UC (mUC), enfortumab vedotin (EV) targets NECTIN4, a protein which is expressed on the cell surface of bladder cancer cells, and is now the